Provided by Tiger Trade Technology Pte. Ltd.

Atara Biotherapeutics

4.91
-0.2100-4.10%
Post-market: 4.910.00000.00%19:48 EDT
Volume:62.85K
Turnover:314.46K
Market Cap:40.15M
PE:1.91
High:5.26
Open:5.10
Low:4.82
Close:5.12
52wk High:19.15
52wk Low:3.92
Shares:8.18M
Float Shares:5.60M
Volume Ratio:0.33
T/O Rate:1.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.57
EPS(LYR):-11.4053
ROE:-2014.86%
ROA:47.81%
PB:-1.04
PE(LYR):-0.43

Loading ...

Atara Biotherapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Dec 19, 2025

Atara Biotherapeutics Inc : Mizuho Raises Target Price to $18 From $16

THOMSON REUTERS
·
Nov 21, 2025

Atara Biotherapeutics price target raised to $18 from $16 at Mizuho

TIPRANKS
·
Nov 21, 2025

Top Executives Make Significant Moves with Atara Biotherapeutics Stock!

TIPRANKS
·
Nov 20, 2025

Atara Biotherapeutics Chief Accounting Officer Yanina Grant-Huerta Reports Disposal of Common Shares

Reuters
·
Nov 20, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 17, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 14, 2025

Atara Biotherapeutics reports Q3 EPS (32c), consensus (67c)

TIPRANKS
·
Nov 12, 2025

Atara Biotherapeutics reduces workforce by 29%

TIPRANKS
·
Nov 12, 2025

Atara Biotherapeutics Q3 revenue beats estimates

Reuters
·
Nov 12, 2025

Atara Biotherapeutics Q3 EPS $(0.32) Beats $(0.86) Estimate, Sales $3.453M Beat $1.398M Estimate

Benzinga
·
Nov 12, 2025

BRIEF-Atara Biotherapeutics Q3 EPS USD -0.32

Reuters
·
Nov 12, 2025

Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress

THOMSON REUTERS
·
Nov 12, 2025

Atara Biotherapeutics Inc: Anticipate Full-Year 2025 Operating Expenses Will Decrease by at Least 60% Compared to 2024

THOMSON REUTERS
·
Nov 12, 2025

Atara Biotherapeutics Q3 Revenue USD 3.453 Million

THOMSON REUTERS
·
Nov 12, 2025

Top News Today/Canada: Barrick's Interim CEO Gets to Work

Dow Jones
·
Nov 11, 2025

Atara Biotherapeutics Inc expected to post a loss of 86 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025

FDA Accepts Tabelecleucel BLA for Priority Review with PDUFA Date Set for January 2026

Reuters
·
Nov 03, 2025

Pierre Fabre Pharmaceuticals Announces Transfer From Atara Biotherapeutics of the Biologics License Application (Bla) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (Ebv+ Ptld)

THOMSON REUTERS
·
Nov 03, 2025

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 30% Though Its Price And Business Still Lag The Industry

Simply Wall St.
·
Oct 09, 2025